Strategy

COMPANY DIRECTION

CanaQuest is a clinical-stage life sciences company focused on developing innovative cannabinoid-based therapeutics. Our primary focus is CQ-001, a proprietary drug candidate that combines cannabidiol (CBD) with Omega-3 fatty acids.

Mission

mission strategy image

Our mission is to treat 30%-40% of the 65 million people worldwide who suffer from refractory epilepsy, which is not effectively treatable with current anti-epileptic drugs, excluding CBD-based medications.

Value Proposition: CQ-001 leverages the synergistic effects of CBD and Omega-3s to enhance binding to critical PPAR receptors in the brain. This synergy has demonstrated a 35% increase in potency compared to isolated CBD in pre-clinical epilepsy models.

Our expertise in cannabinoid therapeutics is well-established, particularly with the FDA-approved cannabidiol (Epidiolex®), positioning us at the forefront of epilepsy treatment innovation.

CanaQuest’s strategy includes:

Scientific Development: Continue perfecting our scientifically backed proprietary formulations with our scientific team, supported by pre-clinical trial results.
Clinical Trials: Conduct clinical trials for drug candidate CQ-001 in collaboration with partners.
Global Partnerships: Partner with a global pharmaceutical organization to enhance our reach and capabilities.

Strategic Focus:

CanaQuest is pursuing the same regulatory pathway that GW Pharma used to obtain approvals for Epidiolex, specifically targeting refractory epilepsy, which is not effectively treatable with current anti-epileptic drugs,

Regulatory Pathways: We have mapped out regulatory pathways for CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for rare neurological conditions related to epilepsy, with projected approvals in about three years.

Pre-Clinical Success: Pre-clinical trials completed at Western University and the Ontario Brain Institute have demonstrated CQ-001’s synergistic effects, showing a 35% increase in potency compared to isolated CBD. This indicates significant effectiveness in protecting against seizure activity.
Enhanced Potency and Safety: The combination of CBD and the proprietary API composition in CQ-001 has shown potentiation, suggesting lower dosages may achieve similar efficacy, potentially translating to a safer side effect profile.

Drug Candidate – CQ-001: CQ-001 aims to offer superior benefits compared to existing treatments like Epidiolex® at lower dosages and with reduced side effects. It targets neurological conditions such as epilepsy, PTSD, and anxiety. CanaQuest’s advanced research and promising pre-clinical results position it as a leader in next-generation cannabinoid therapies, presenting a compelling investment opportunity.

Accumulated Expertise: To commercialize and obtain regulatory approvals for CQ-001, CanaQuest has assembled a strong team of consultants and advisors with extensive experience in cannabinoid therapeutics:

1. Dr. Jordyn Stuart, Ph.D., BS, BS – Acting Chief Scientific Officer: With 12 years of pre-clinical cannabinoid research experience, including six years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma), Dr. Stuart was involved in the launch of Epidiolex®.
2. Dr. Paul Dick, DVM, MSc – Chairman of Advisory Board: With over 30 years of experience in the pharmaceutical and animal health industries, Dr. Dick has served on several boards, including the Animal Health Institute and the Ontario Veterinary Medical Association.
3. Eddie Francis, MS – Interim Chief Operating Officer: With a background in Molecular Biology and Oncology, Eddie has over ten years of experience in the natural therapeutic sector and 20 years in the private sector, focusing on mental health and wellness initiatives.

We have also secured ongoing relationships with trusted legal, regulatory, and compliance advisors to advance our business.

Regulatory Approval Process: CanaQuest is positioned to submit New Drug Applications (NDAs) to Health Canada and the US FDA for Phase II/III clinical trials, with approval projected to take approximately two years in Canada and three years in the US. We acknowledge the inherent risks and uncertainties in the regulatory approval process, including regulatory requirements, clinical trial outcomes, and potential unforeseen challenges.

Partnerships: CanaQuest has established partnerships with Neeka Health for clinical trial expertise and the NHL Alumni Association for clinical studies. These partnerships will investigate CQ-001’s potential applications across various indications, paving the way for future clinical trials.

Market Strategy: CanaQuest aims to introduce CQ-001 into markets currently dominated by Epidiolex®. By enhancing CQ-001’s efficacy, the company projects substantial revenues post-approval in the US and Canada. Additionally, CanaQuest is exploring applications beyond epilepsy, including inflammation-related conditions and veterinary pharmaceuticals.

Advisor Shared Values and Expertise

Shared passion to make a real difference in quality of life
Scientific knowledge and expertise in cannabinoid-based medicine
Currently or amenable to prescribing cannabinoids.

Strategic Focus

The Company is following the same regulatory pathway that GW Pharma took to obtain approvals for Epidiolex to treat Dravet & Lennox Gastaut Syndromes, rare neurological conditions under the umbrella of epilepsy.

Regulatory pathways are mapped out for RX CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, with projected approvals in about 3 years.

Pre-clinical trials have been completed by Western University for Rx CQ-001 & Rx CQ-002.

Drug candidate, Rx CQ-001, supported by (CBD molecules + formula) – molecules bond and synergistically attach to PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this.

Epidiolex Formula is 99% CBD – sesame as carrier oil (non-active).